Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitro

• Published in: Experimental and molecular pathology 2011-12, Vol.91 (3), p.733-739
• Main Authors: Bauer, Sabrina, Weiss, Thomas S., Wiest, Reiner, Schacherer, Doris, Hellerbrand, Claus, Farkas, Stefan, Scherer, Marcus N., Ritter, Mirko, Schmitz, Gerd, Schäffler, Andreas, Buechler, Christa
• Format: Article
• Language: English
• Subjects: Aged; Antigens, CD - biosynthesis; Antigens, CD - immunology; Antigens, Differentiation, Myelomonocytic - biosynthesis; Antigens, Differentiation, Myelomonocytic - immunology; Biological and medical sciences; CD163; Cells, Cultured; Down-Regulation; Fatty Acids, Nonesterified - metabolism; Fatty liver; Fatty Liver - immunology; Fatty Liver - metabolism; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Intra-Abdominal Fat - immunology; Intra-Abdominal Fat - metabolism; Investigative techniques, diagnostic techniques (general aspects); Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Monocyte; Monocytes - immunology; Monocytes - metabolism; Other diseases. Semiology; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Portal vein; Receptors, Cell Surface - biosynthesis; Receptors, Cell Surface - immunology; RNA, Messenger - analysis; Up-Regulation
• ISSN: 0014-4800; 1096-0945
• DOI: 10.1016/j.yexmp.2011.07.005

Visceral fat differs from subcutaneous fat by higher local inflammation and increased release of IL-6 and free fatty acids (FFA) which contribute to hepatic steatosis. IL-6 has been shown to upregulate the monocyte/macrophage specific receptor CD163 whose soluble form, sCD163, is increased in inflammatory diseases. Here, it was analyzed whether CD163 and sCD163 are differentially expressed in the human fat depots and fatty liver. CD163 mRNA and protein were similarly expressed in paired samples of human visceral and subcutaneous fat, and comparable levels in portal venous and systemic venous blood of liver-healthy controls indicate that release of sCD163 from visceral adipose tissue was not increased. CD163 was also similarly expressed in steatotic liver when compared to non-steatotic tissues and sCD163 was almost equal in the respective sera. Concentrations of sCD163 were not affected when passing the liver excluding substantial hepatic removal/release of this protein. A high concentration of IL-6 upregulated CD163 protein while physiological doses had no effect. However, sCD163 was not increased by any of the IL-6 doses tested. FFA even modestly decreased CD163 and sCD163. The anti-inflammatory mediators fenofibrate, pioglitazone, and eicosapentaenoic acid (EPA) did not influence sCD163 levels while CD163 was reduced by EPA. These data suggest that in humans neither visceral fat nor fatty liver are major sources of sCD163. ► Visceral fat differs from subcutaneous fat by higher local inflammation and increased release of IL-6 and free fatty acids (FFA) which contribute to hepatic steatosis. ► CD163 is similarly expressed in the human fat depots and in steatotic and non-steatotic liver. ► Soluble CD163 is not increased in serum of patients with fatty liver and production in visceral fat seems to be similar to subcutaneous fat. ► The anti-inflammatory mediators fenofibrate, pioglitazone, and eicosapentaenoic acid (EPA) do not alter sCD163 levels while CD163 is reduced by EPA.